Prevalence of Epstein–Barr virus antibodies in different age groups in Europe and Asia: a systematic review and meta-analysis

Мұқаба

Дәйексөз келтіру

Толық мәтін

Аннотация

Introduction. Attempts to assess the prevalence of antibodies (seroprevalence) to the Epstein–Barr virus have been made several times. Still, a complete understanding of this issue has not been reached due to the small samples of the surveyed. The goal is to evaluate seroprevalence in different age groups in Europe and Asia using a systematic review and meta-analysis.

Material and methods. The search for publications was carried out on PubMed, Cochrane Reviews/CochraneLibrary, eLibrary, Cyberleninka, Researchgate from May 6 to 30, 2020. A total of 2,364 articles were found, 12 of which were included in the study. Seroprevalence to Epstein–Barr virus was determined in 67,561 individuals aged 0 to 80 years. The research results were distributed by age groups, continents (Europe and Asia), and their implementation (2000–2012 and 2013–2019) and subjected to meta-analysis.

Results. Minimal seroprevalence was detected among children under 1 and 1–2 years of age (53.3 and 50.9%). With increasing age, it grew, and people over 18 years of age were more than 90%. In 2013–2019, the index value (68.9%) was significantly higher than in 2000–2012 (89.6%). In Asian countries in 2000–2019, seroprevalence (86.7%) was considerably higher than in Europe (76.3%). The highest growth rate was observed in 7–14 years. In 2000-2012, the maximum growth rate of seroprevalence occurred in 15–17 years and 2013–2019 – 3–6 years. For all age groups, the growth rate was higher in Europe than in Asia and 2013–2019 compared to 2000–2012.

Conclusion. The meta-analysis revealed differences in seroprevalence depending on age and territory of residence and the growth of indices in the trend.

Contribution of the authors:

Solomay T.V. — concept and design of research, collection and processing of material, statistical processing, text writing;

Semenenko T.A. — concept and design of research, collection and processing of material, editing;

Blokh A.I. — collection and processing of material, statistical processing, text writing.

All authors are responsible for the integrity of all parts of the manuscript and approval of the manuscript final version.

Acknowledgements. The study had no sponsorship.

Conflict of interest. The authors declare no conflict of interest.

Авторлар туралы

Tatyana Solomay

Interregional Department № 1 of the Federal Medical and Biological Agency; I.I. Mechnikov Research Institute of Vaccines and Serums

Хат алмасуға жауапты Автор.
Email: solomay@rambler.ru
ORCID iD: 0000-0002-7040-7653

MD, PhD, Deputy head of Interregional Department №1 of the FMBA of Russia, Moscow, 123182; senior researcher, laboratory of epidemiological analysis and monitoring of infectious diseases, I.I. Mechnikov Research Institute of Vaccines and Serums, Moscow, 105064, Russian Federation.

e-mail: solomay@rambler.ru

Ресей

Tatyana Semenenko

N.F. Gamaleya National Research Center of Epidemiology and Microbiology; Sechenov First Moscow State Medical University (Sechenov University)

Email: noemail@neicon.ru
ORCID iD: 0000-0002-6686-9011
Ресей

Alexey Blokh

Omsk State Medical University; Omsk Research Institute of Natural Focal Infections

Email: noemail@neicon.ru
ORCID iD: 0000-0002-0756-2271
Ресей

Әдебиет тізімі

  1. Sharifipour S., Davoodi Rad K. Seroprevalence of Epstein–Barr virus among children and adults in Tehran, Iran. New Microbes New Infect. 2020; 34: 100641. https://doi.org/10.1016/j.nmni.2019.100641
  2. Huang Y., Wei C., Zheng K., Zhao D. The impact of serological features in Chinese children with primary or past Epstein–Barr virus infections. Virol. J. 2013; 10: 55. https://doi.org/10.1186/1743-422X-10-55
  3. Chan K.H., Tam J.S., Peiris J.S., Seto W.H., Ng M.H. Epstein–Barr virus (EBV) infection in infancy. J. Clin. Virol. 2001; 21(1): 57–62. https://doi.org/10.1016/s1386-6532(01)00149-4
  4. Cui J., Yan W., Xu S., Wang Q., Zhang W., Liu W., et al. Anti-Epstein–Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients. PLoS One. 2018; 13(3): e0193171. https://doi.org/10.1371/journal.pone.0193171
  5. Xiong G., Zhang B., Huang M.Y., Zhou H., Chen L.Z., Feng Q.S., et al. Epstein–Barr virus (EBV) infection in Chinese children: a retrospective study of age-specific prevalence. PLoS One. 2014; 9(6): e99857. https://doi.org/10.1371/journal.pone.0099857
  6. Beader N., Kolarić B., Slačanac D., Tabain I., Vilibić-Čavlek T. Seroepidemiological study of Epstein–Barr virus in different population groups in Croatia. Isr. Med. Assoc. J. 2018; 20(2): 86–90.
  7. Zhebrun A.B., Kulyashova L.B., Ermolenko K.D., Zakrevskaya A.V. Spread of Herpesvirus infections in children and adults in St. Petersburg according to seroepidemiologic study data. Zhurnal mikrobiologii, epidemiologii i immunobiologii. 2013; 90(6): 30–6. (in Russian)
  8. Smatti M.K., Yassine H.M., Abu Odeh R., Al Marawani A., Taleb SA., Althani A.A., et al. Prevalence and molecular profiling of Epstein–Barr virus (EBV) among healthy blood donors from different nationalities in Qatar. PLoS One. 2017; 12(12): e0189033. https://doi.org/10.1371/journal.pone.0189033
  9. Kotlova V.B., Kokoreva S.P., Makarova A.V. Epstein–Barr viral infection and pregnancy. Vestnik novykh meditsinskikh tekhnologiy. 2013; (1). Available at: https://cyberleninka.ru/article/n/epshteyna-barr-virusnaya-infektsiya-i-beremennost (in Russian)
  10. Pembrey L., Raynor P., Griffiths P., Chaytor S., Wright J., Hall A.J. Seroprevalence of cytomegalovirus, Epstein–Barr virus and varicella zoster virus among pregnant women in Bradford: a cohort study. PLoS One. 2013; 8(11): e81881.https://doi.org/10.1371/journal.pone.0081881
  11. Fourcade G., Germi R., Guerber F., Lupo J., Baccard M., Seigneurin A., et al. Evolution of EBV seroprevalence and primary infection age in a French hospital and a city laboratory network, 2000-2016. PLoS One. 2017; 12(4): e0175574. https://doi.org/10.1371/journal.pone.0175574
  12. Abrahamyan S., Eberspächer B., Hoshi M.M., Aly L., Luessi F., Groppa S., et al. Competence Network Multiple Sclerosis (KKNMS); Other members of the KKNMS that acted as collaborators in this study. Complete Epstein–Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 2020; 91(7): 681–6. https://doi.org/10.1136/jnnp-2020-322941
  13. Solomay T.V. Dynamics of morbidity and territorial spread of infectious mononucleosis. Zdravookhranenie Rossiyskoy Federatsii. 2019; 63(4): 186–92. https://doi.org/10.18821/0044-197X-2019-63-4-186-192 (in Russian)
  14. Solomay T.V., Semenenko T.A., Karazhas N.V., Rybalkina T.N., Kornienko M.N., Bosh’yan R.E., et al. Assessing risks of infection with herpes viruses during transfusion of donor blood and its components. Analiz riska zdorov’yu. 2020; (2): 135–42. https://doi.org/10.21668/health.risk/2020.2.15.eng (in Russian)
  15. Antonova M.V., Kashuba E.A., Drozdova T.G., Lyubimtseva O.A., Khanipova L.V., Ogoshkova N.V., et al. Comparative characteristics of the clinical course and laboratory parameters of the primary and reactivation of Epstein-Barr virus infection in children ofdifferent ages groups. Vestnik soveta molodykh uchenykh i spetsialistov Chelyabinskoy oblasti. 2016; 2(3): 19–24. (in Russian)
  16. Germi R., Guigue N., Lupo J., Semenova T., Grossi L., Vermeulen O., et al. Methylation of Epstein–Barr virus Rta promoter in EBV primary infection, reactivation and lymphoproliferation. J. Med. Virol. 2016; 88(10): 1814–20. https://doi.org/10.1002/jmv.24524
  17. Kawamoto K., Miyoshi H., Seto M., Kimura H., Ohshima K. Clinical features of adult-onset chronic active Epstein–Barr virus infection. Rinsho Ketsueki. 2019; 60(8): 944–52. https://doi.org/10.11406/rinketsu.60.944 (in Japanese)
  18. Vofo B.N., Ngankam G.V.F., Ngwasiri C.A., Atem J.A., Aminde L.N. Acute blindness as a presenting sign of childhood endemic lymphoma in Cameroon: a case report. J. Med. Case Rep. 2018; 12(1): 129. https://doi.org/10.1186/s13256-018-1682-3
  19. Mawson A.R., Majumdar S. Malaria, Epstein–Barr virus infection and the pathogenesis of Burkitt’s lymphoma. Int. J. Cancer. 2017; 141(9): 1849–55. https://doi.org/10.1002/ijc.30885
  20. Tawfik K., Liron Y., Ayman A.R., Schneider R., Wolf D.G., Ronen L. A heart breaking case of rapidly developing severe hemophagocytic syndrome secondary to chronic active infection; a case report and review of the literature. J. Clin. Virol. 2015; 67: 14–6. https://doi.org/10.1016/j.jcv.2015.03.017
  21. Solomay T.V., Semenenko T.A., Ivanova M.Yu. The role of Epstein–Barr viral infection and hepatitis B and C in liver pathology. Voprosy virusologii. 2019; 64(5): 215–20. https://doi.org/10.36233/0507-4088-2019-64-5-215-220 (in Russian)
  22. Solomay T.V., Semenenko T.A. Viral hepatitis B, C and infectious mononucleosis: epidemiological similarities and differences. Voprosy virusologii. 2020; 65(1): 27–34. https://doi.org/10.36233/0507-4088-2020-65-1-27-34 (in Russian)
  23. Moutschen M., Léonard P., Sokal E.M., Smets F., Haumont M., Mazzu P., et al. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein–Barr virus vaccine in healthy adults. Vaccine. 2007; 25(24): 4697–705. https://doi.org/10.1016/j.vaccine.2007.04.008
  24. Sokal E.M., Hoppenbrouwers K., Vandermeulen C., Moutschen M., Léonard P., Moreels A., et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein–Barr Virus vaccine in healthy young adults. J. Infect. Dis. 2007; 196(12): 1749–53. https://doi.org/10.1086/523813
  25. Taylor G.S., Jia H., Harrington K., Lee L.W., Turner J., Ladell K., et al. A recombinant modified vaccinia Ankara vaccine encoding Epstein–Barr virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin. Cancer Res. 2014; 20(19): 5009–22. https://doi.org/10.1158/1078-0432.CCR-14-1122-T
  26. Barendregt J.J., Doi S.A., Lee Y.Y., Norman R.E., Vos T. Meta-analysis of prevalence. J. Epidemiol. Community Health. 2013; 67(11): 974–8. https://doi.org/10.1136/jech-2013-203104
  27. Brodley C.E., Lau J., Schmid C.H. Open meta-analyst. 2012. Available at: http://www.cebm.brown.edu/openmeta/downloads/open_meta_analyst_win8.zip
  28. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analysis. Br. Med. J. 2003; 327(7414): 557–60. https://doi.org/10.1136/bmj.327.7414.557
  29. Borenstein M., Higgins J.P., Hedges L.V., Rothstein H.R. Basics of meta-analysis: I (2) is not an absolute measure of heterogeneity. Res. Synth. Methods. 2017; 8(1): 5–18. https://doi.org/10.1002/jrsm.1230
  30. Reynaldi A., Schlub T.E., Piriou E., Ogolla S., Sumba O.P., Moormann A.M., et al. Modeling of EBV infection and responses in Kenyan infants with different levels of malaria exposure shows decay is a major determinant of early EBV infection. J. Infect. Dis. 2016; 214(9): 1390–8. https://doi.org/10.1093/infdis/jiw396
  31. Ogolla S., Daud I.I., Asito A.S., Sumba O.P., Ouma C., Vulule J., et al. Reduced transplacental transfer of a subset of Epstein–Barr virus-specific antibodies to neonates of mothers infected with plasmodium falciparum malaria during pregnancy. Clin. Vaccine Immunol. 2015; 22(11): 1197–205. https://doi.org/10.1128/CVI.00270-15
  32. Womack J., Jimenez M. Common questions about infectious mononucleosis. Am. Fam. Physician. 2015; 91(6): 372–6.
  33. Goncharova E.V., Senyuta N.B., Smirnova K.V., Shcherbak L.N., Gurtsevich V.E. Epstein–Barr virus (EBV) in Russia: infection of the population and analysis of the LMP1 gene variants in patients with EBV-associated pathologies and healthy individuals. Voprosy virusologii. 2015; 60(2): 11–7. (in Russian)

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Solomay T.V., Semenenko T.A., Blokh A.I., 2021

Creative Commons License
Бұл мақала лицензия бойынша қолжетімді Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ:  ПИ № ФС77-50668 от 13.07.2012 г.